Effects of beraprost sodium, a prostacyclin analogue, on diabetic neuropathy in streptozotocin-induced diabetic rats

Japanese Journal of Pharmacology

Volumn 70, Issue 2, 1996, Pages 177-182

  Ueno, Yuji ^a   Koike, Hiroshi ^a   Nakamura, Yukiko ^a   Ochi, Yasuo ^a   Annoh, Shigeyasu ^a   Nishio, Shintaro ^a  

^a TORAY INDUSTRIES INC   (Japan)

Author keywords

Beraprost sodium; Morphological analysis; Motor nerve conduction velocity; Nerve blood flow

Indexed keywords

BERAPROST; EPALRESTAT; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; BODY WEIGHT; CELL SIZE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; MALE; MORPHOMETRICS; MOTOR NERVE CONDUCTION; MYELINATED NERVE; NERVE FIBER; NONHUMAN; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0029933434     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.70.177     Document Type: Article

References (25)

1. Tuck RR, Schmerzer JD and Low PA: Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 107, 935-950 (1984)
2. Low PA, Tuck RR, Dyck PJ, Schmerzer JD and Yao JK: Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. Proc Natl Acad Sci USA 81, 6894-6898 (1984)
3. Dyck PJ, Hansen S and Karnes J: Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci USA 82, 2513-2517 (1985)
4. Johnson PC, Doll SC and Cromey DC: Pathogenesis of diabetic neuropathy. Ann Neurol 19, 450-457 (1986)
5. Yasuda H and Dyck PJ: Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. Neurology 37, 20-28 (1987)
6. Dyck PJ: Hypoxic neuropathy: does hypoxia play a role in diabetic neuropathy? Neurology 39, 111-118(1989)
7. Bunting S, Gryglewski R, Moncada S and Vane JR: Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin x) which relaxes strips of mesenteric and coeliac and inhibits platelet aggregation. Prostaglandins 12, 897-913 (1976)
8. Moncada S, Gryglewski R, Bunting S and Vane JR: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263, 663-665 (1976)
9. 2 analogue. Jpn J Pharmacol 43, 81-89 (1987)
10. Nishio S, Matsuura H, Kanai N, Fukatsu Y, Hirano T, Nishikawa N, Kameoka K and Umetsu T: The in vitro and ex vivo anti-platelet effect of TRK-100, a stable prostacyclin analog, in several species. Jpn J Pharmacol 47, 1-10 (1988)
11. Sim AK, McCraw AP, Cleland ME, Nishio S and Umetsu T: Effects of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation. Arzneimittelforschung 35, 1816-1818 (1985)
12. Ueno Y, Kawashima A, Koike H and Nishio S: Effect of beraprost sodium, a stable prostacyclin analogue, on pulmonary thromboembolism in mice. Thromb Res 77, 193-198 (1995)
13. Akiba T, Miyazaki M and Toda N: Vasodilator actions of TRK-100, a new prostaglandin I, analogue. Br J Pharmacol 89, 703-711 (1986)
14. Ward KK, Low PA, Schmelzer ID and Zochodne DW: Prostacyclin and noradrenaline in peripheral nerve of chronic experimental diabetes in rats. Brain 112, 197-205 (1989)
15. Shindo H, Tawata M, Aida K and Onaya T: Clinical efficacy of a stable prostacyclin analog, iloprost, in diabetic neurophathy. Prostaglandins 41, 85-96 (1991)
16. O'mally BC, Timperley WR, Ward JD, Porter NR and Preston FE: Platelet abnormalities in diabetic peripheral neuropathy. Lancet 27, 1274-1276 (1975)
17. Colwell JA, Halushka PV, Sarji J, Sagel J and Nair RMG: Altered platelet function in diabetes mellitus. Diabetes 25, Supp 2, 826-831 (1976)
18. 2 by diabetic platelets. Eur J Clin Invest 9, 223-228 (1979)
19. Wada K, Takiguti Y and Nakashima M: Changes in platelet aggregation in whole blood, plasma and washed platelets in streptozotocin-induced diabetic rats; Time-dependent change in the antiaggregatofy activity of diabetic rats plasma. Platelets 4, 280-284 (1993)
20. Simpson LO: Altered blood rheology in the pathogenesis of diabetic and other neropathies. Muscle Nerve 11, 725-744 (1988)
21. Hirano T, Nishimura S and Fukatsu Y: Effect of beraprost sodium (TRK-100) on erythrocyte deformability, blood viscosity and thrombus formation in rats. Jpn J Thromb Hemostas 2, 94-105 (1990) (Abstr in English)
22. Bohlen HG and Hankins KD: Early arteriolar and capillary changes in streptozotocin-induced diabetic rats and intraperitoneal hyperglycemic rats. Diabetologia 22, 344-348 (1982)
23. Joyner WL, Mayhan WG, Johnson RL and Phares CK: Microvascular alterations develop in syrian hamsters after the induction of diabetes mellitus by streptozotocin. Diabetes 30, 93-100 (1981)
24. 1 analogue TFC 612 on diabetic neuropthy in streptozotocin-induced diabetic rats. Diabetes 38, 832-838 (1989)
25. Kato N, Mizuno K, Matsubara A, Nakano K, Kurono M and Yagihashi S: Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2′,5′-dioxospiro-[chroman-4,4′-imidazolidine] -2-carboxamide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats. J Diabetes Complications 8, 27-32 (1994)